Particle Identification
Observing visible and subvisible particles can stagnate the drug development or the batch release process. Coriolis Pharma has the experience and the capacity to determine the identity and possible origin of particulate matter in your biopharmaceutical drug products—crucial for troubleshooting and root-cause analysis. Our experts can analyze your samples with minimal lead time and deliver results from the lab bench so you can resolve the underlying cause of particle formation.
Particle Identification Tailored to Your Needs
Particles in the visible and subvisible size range can appear in biopharmaceutical samples and drug products during all stages of development and even after market approval. The presence of particles can negatively influence the safety and efficacy of the therapy.
They can be introduced to a therapeutic in several different ways, including:
- Directly derived from the active pharmaceutical ingredient (API), for example, due to an insufficiently stable therapeutic protein (intrinsic particles)
- Be introduced by formulation excipients, for example, as degradation products or particulate impurities (inherent particles)
- Be generated by the production process, for example, during pumping or filtration steps (extrinsic particles)
Troubleshooting with Rapid Particle Identification
Determining the identity and possible origin of particulate matter in biopharmaceutical drug products is crucial for troubleshooting and root-cause analysis, and therefore, it is often very time sensitive. If required, Coriolis experts can analyze your samples within a matter of days so you can quickly resolve the underlying cause of particle formation.
Particle Identification Testing Methods
We can select the most suitable approach for your analytical challenge, whether following a standardized in-house workflow or a custom-tailored solution.
Analytical Method Development, Qualification and Validation
For common sample types, we can often apply standardized methods with little setup effort. However, when needed, our experienced analytical experts create or optimize custom methods tailored to your active pharmaceutical ingredient, product type and development phase.
Particle Identification for Your Drug Product
Coriolis Pharma’s deep expertise across many biologic modalities, combined with input from world-leading external advisors, offers the knowledge and experience needed to solve even the most complex formulation and drug development challenges.
Your Phase
Our expert team has the expertise and experience to guide your biopharmaceutical development program from preclinical and early-phase development to the market.
Particle Identification Resources
Publications
April 1, 2024
Publications
July 1, 2020
Publications
November 1, 2019